HoldsUp

Robert H. Lustig

Robert H. Lustig is a researcher and author focused on pediatric health, nutrition, and metabolic disease. His published research investigates the biochemical and environmental mechanisms driving obesity, including the health impacts of dietary fructose, ultraprocessed foods, and chemical obesogens. He also studies pediatric endocrine and growth outcomes, food addiction, and the influence of industry practices on chronic disease.

43 claims checked on air: 6 context 7 contradicted 7 overstated 17 supported 6 unverified

What they said on air

2 citing their own research

0:04:03supportedhighTake Back Your Health - with Dr. Robert H. Lustig | The Empo

The hormone leptin was discovered in 1994.

"that really started my obesity career, was the discovery of leptin in 1994." (said at 0:04:03)

The hormone leptin (the product of the obese/ob gene) was identified and cloned by Jeffrey Friedman and colleagues in 1994, a landmark discovery that established adipose tissue as an active endocrine organ regulating energy balance.

0:06:35supportedvery lowTake Back Your Health - with Dr. Robert H. Lustig | The Empo

In animal studies, lesioning the hypothalamus causes hypothalamic obesity by placing the neural connection between the brain and the pancreas for insulin release into hyperdrive.

"And so lesioning the hypothalamus led to this obesity syndrome in rats called hypothalamic obesity. And what was determined was that the reason that those rats gained so much weight was because the connection between the brain and the pancreas to release insulin was in hyperdrive." (said at 0:06:35)

Classic animal experiments established that lesions to the ventromedial hypothalamus (VMH) in rodents produce rapid hyperinsulinemia and hypothalamic obesity primarily driven by parasympathetic (vagus nerve) overactivity connecting the brain to the pancreatic beta-cells. Studies demonstrated that acute post-lesion hyperinsulinemia is abolished by subdiaphragmatic vagotomy, and that transplanting denervated pancreatic tissue to the kidney capsule prevents the development of hyperinsulinemia and hypothalamic obesity after VMH lesions. Because this evidence is derived entirely from animal models, the certainty of evidence is graded as very low.

0:07:36supportedmoderateTake Back Your Health - with Dr. Robert H. Lustig | The Empo

In pediatric patients with hypothalamic obesity, administering octreotide suppressed insulin release, resulting in weight loss, spontaneous physical activity, and quality-of-life improvements that correlated directly with the degree of insulin suppression.

"So in a clinical research protocol, we gave kids with this disorder this drug, octreotide, to suppress insulin. And lo and behold, not only did they lose weight—which was remarkable enough because these kids only gained weight and fast, so that was remarkable on its own—but they started exercising spontaneously... and it turned out the degree of quality of life improvement correlated with the degree of insulin suppression: the lower we got the insulin, the better these kids felt." (said at 0:07:36)

Published clinical trials led by the speaker directly support this claim. In an open-label pilot study of 8 pediatric patients with hypothalamic obesity (PMID 10431109), octreotide administration suppressed excessive insulin secretion during oral glucose tolerance testing and led to significant weight loss (-4.8 kg vs +6.0 kg pre-study). In a subsequent randomized, double-blind, placebo-controlled trial of 18 children (PMID 12788859), octreotide suppressed insulin response (P = 0.034), significantly reduced weight gain and BMI (+1.6 kg vs +9.1 kg for placebo, P < 0.001; BMI -0.2 vs +2.2 kg/m²), improved physical activity per parent report (P = 0.03), and demonstrated quality-of-life improvements that directly correlated with the degree of insulin suppression (P = 0.041). The certainty is moderate given the randomized controlled design, limited by the small sample size inherent to this rare condition.

0:10:09supportedmoderateTake Back Your Health - with Dr. Robert H. Lustig | The Empo

Excess circulating insulin activates intracellular pathways leading to vascular smooth muscle proliferation, reduced cellular autophagy, and an increased risk of cancer.

"And the problem is if you have too much, you activate a whole set of other pathways in the cell, all of which lead to vascular smooth muscle proliferation, reduced autophagy, and increased risk for cancer." (said at 0:10:09)

The speaker accurately summarizes well-established physiological and molecular actions of elevated insulin signaling. Insulin stimulates vascular smooth muscle cell (VSMC) proliferation and migration primarily through the mitogen-activated protein kinase (MAPK) pathway. Concurrently, activation of the PI3K/Akt/mTOR pathway by insulin suppresses macroautophagy. Chronic hyperinsulinemia is also well recognized in epidemiological and mechanistic literature as a driver of increased risk and progression for several types of cancer through its mitogenic and anti-apoptotic signaling.

0:11:11supportedhighTake Back Your Health - with Dr. Robert H. Lustig | The Empo

The insulin receptor is coupled to the mitogen-activated protein kinase (MAP kinase) pathway, which stimulates cell growth and division.

"There is—the insulin receptor is coupled to a pathway in the cell that basically makes cells grow and divide. It's called MAP kinase, mitogen-activated protein kinase, and that pathway is very important when you are growing, like for instance a fetus." (said at 0:11:11)

The speaker accurately described the canonical signaling pathway downstream of the insulin receptor. Insulin binding leads to phosphorylation of insulin receptor substrates (such as IRS-1), which couples to the mitogen-activated protein kinase (MAPK/ERK) cascade to stimulate cellular growth, division, and mitogenesis. This signaling mechanism plays a key role in cellular proliferation and developmental processes, including fetal growth.

0:15:40needs contextmoderatetheir own paperTake Back Your Health - with Dr. Robert H. Lustig | The Empo

Fructose and alcohol are metabolized by the liver in virtually identical biochemical pathways after the initial glycolysis step.

"Well, turns out sugar, the molecule fructose, the sweet molecule in sugar, and alcohol are metabolized by the liver virtually identically... The big difference between sugar and alcohol is that for alcohol, the yeast does the first step of metabolism called glycolysis. For sugar, we do our own first step. But after that, the liver can't tell the difference as to where it came from." (said at 0:15:40)

The speaker is describing a well-known metabolic parallel popularized in the nutritional literature comparing the downstream hepatic fates of fructose and ethanol. Both bypass standard hepatic insulin-regulated checkpoints (such as phosphofructokinase for glucose), generating an unregulated influx of substrates (acetyl-CoA) that overwhelms mitochondrial capacity and promotes de novo lipogenesis, hepatic steatosis, and reactive oxygen species. However, describing their metabolism as "virtually identical" after an initial step is an oversimplification: ethanol is oxidized via alcohol dehydrogenase and aldehyde dehydrogenase into acetate and acetyl-CoA, whereas fructose is processed through fructokinase and aldolase B into three-carbon glycolytic intermediates (glyceraldehyde and dihydroxyacetone phosphate) before progressing to pyruvate, acetyl-CoA, gluconeogenesis, or glycogen synthesis.

0:16:45overstatedmoderateTake Back Your Health - with Dr. Robert H. Lustig | The Empo

Approximately 25% of all children in the United States have non-alcoholic fatty liver disease.

"and in fact 25% of the entire pediatric population of the United States have fatty liver." (said at 0:16:45)

The ~25% prevalence figure comes from recent National Health and Nutrition Examination Survey (NHANES 2017–2020) data evaluating US adolescents (ages 12–19) using transient elastography (controlled attenuation parameter), which identified a non-alcoholic fatty liver disease (NAFLD) prevalence of 25.8% (and metabolic dysfunction-associated steatotic liver disease [MASLD] prevalence of 20–23%). However, applying this figure to the 'entire pediatric population' overstates the prevalence across all childhood ages, as fatty liver disease is significantly less common in younger children, yielding an overall pediatric prevalence estimated at roughly 7% to 10% in general populations.

0:18:50unverifiedvery lowTake Back Your Health - with Dr. Robert H. Lustig | The Empo

Non-alcoholic fatty liver disease affects 45% of American adults.

"It is 45% of American adults and 25% of American children today, having nothing to do with obesity." (said at 0:18:50)

No published record matching the claim that non-alcoholic fatty liver disease affects 45% of American adults was located; this does not prove the claim false.

0:19:15needs contextmoderateTake Back Your Health - with Dr. Robert H. Lustig | The Empo

88% of adults in the United States have insulin resistance or metabolic dysfunction.

"and 88% of Americans have insulin resistance, have metabolic dysfunction because their liver is overwhelmed." (said at 0:19:15)

The 88% figure derives from a nationally representative cross-sectional study of NHANES 2009-2016 data (Araújo et al., 2019, n=8,721), which found that only 12.2% of US adults met all five criteria for optimal cardiometabolic health (optimal waist circumference, fasting glucose/HbA1c, blood pressure, triglycerides, and HDL cholesterol, without related medications). Consequently, 87.8% of adults had at least one suboptimal cardiometabolic risk factor. However, having a single non-optimal marker (such as prehypertension or elevated waist circumference) is not equivalent to having clinical insulin resistance, metabolic syndrome, or liver-driven metabolic dysfunction.

0:19:22contradictedhighTake Back Your Health - with Dr. Robert H. Lustig | The Empo

There are more metabolically unhealthy normal-weight individuals in the United States than metabolically unhealthy obese individuals.

"And actually it turns out there are more thin, sick people in America than there are fat, sick people" (said at 0:19:22)

Nationally representative data from the National Health and Nutrition Examination Survey (NHANES) contradict the claim that there are more metabolically unhealthy normal-weight individuals ("thin, sick") in the United States than metabolically unhealthy obese individuals ("fat, sick"). An analysis of NHANES data from 1999 to 2018 (PMID: 35691704) found that the prevalence of metabolically unhealthy normal weight was 2.10% (declining from 3.77% in 1999), compared to a prevalence of 26.4% for metabolically unhealthy obesity (increasing from 19.0% in 1999). Even when looking at broader definitions or proportions within BMI categories (PMID: 26841729), approximately 30% of normal-weight US adults are cardiometabolically unhealthy compared to about 71% of obese adults (and 84% of class II/III obese adults), resulting in a substantially larger absolute and relative population of metabolically unhealthy individuals in the overweight and obese categories compared to the normal-weight category.

0:22:56supportedhighTake Back Your Health - with Dr. Robert H. Lustig | The Empo

Fructose is phosphorylated to fructose-1-phosphate in the liver, depleting ATP to ADP and AMP, which is subsequently converted into uric acid.

"So first of all, fructose is phosphorylated in the liver to fructose-1-phosphate. That reduces ATP to ADP, and then that goes to AMP, that goes to uric acid. And that's the reason why sugar causes gout, is because it raises uric acid." (said at 0:22:56)

The biochemical mechanism described by the speaker is well established in metabolic research. In the liver, fructose is rapidly phosphorylated to fructose-1-phosphate by fructokinase (ketohexokinase). Unlike glucose phosphorylation, this step is not tightly regulated by intracellular energy status, leading to transient depletion of intracellular adenosine triphosphate (ATP) and accumulation of adenosine diphosphate (ADP) and adenosine monophosphate (AMP). The excess AMP enters the purine catabolic pathway, resulting in increased production and systemic accumulation of uric acid, which directly links high fructose and sugar intake to hyperuricemia and gout.

0:23:36supportedvery lowTake Back Your Health - with Dr. Robert H. Lustig | The Empo

A 2019 study led by Softic and C. Ronald Kahn showed that glucose stimulates mitochondrial fatty acid oxidation via AMP kinase and hydroxyacyl-CoA dehydrogenase (HADH), whereas fructose inhibits AMP kinase and long-chain acyl-CoA dehydrogenase (ACADL).

"Ron Kahn, the head of the—CEO of Joslin Diabetes Center at Harvard—published a paper, the first author was Softic, S-O-F-T-I-C, in 2019 where he showed that glucose stimulates mitochondrial function through activation of both AMP kinase and HADH, which is hydroxyacyl-CoA dehydrogenase, which is the third step on fatty acid oxidation... Fructose, not only does it inhibit AMP kinase, but it also inhibits another enzyme called ACADL, acyl-CoA dehydrogenase long-chain. And so what happens is the fats build up, and so now you got fatty liver." (said at 0:23:36)

A 2019 mouse study by Softic et al. and C. Ronald Kahn published in Cell Metabolism demonstrated that dietary fructose and glucose exert divergent effects on hepatic mitochondrial function and fatty acid oxidation. Fructose supplementation on a high-fat diet impaired fatty acid oxidation through mechanisms including acetylation and reduced activity of long-chain acyl-CoA dehydrogenase (ACADL) and CPT1a, while glucose supplementation did not impair mitochondrial fat oxidation. Because these findings are derived from preclinical rodent models, the GRADE certainty regarding direct human clinical outcomes is very low, but the speaker's summary accurately reflects the published study's findings and mechanisms.

0:28:32supportedmoderateTake Back Your Health - with Dr. Robert H. Lustig | The Empo

Beta-hydroxybutyrate functions as a signaling molecule that activates sirtuins, stimulating mitochondrial oxidative burning.

"and you're also getting the benefit of the beta-hydroxybutyrate, which is in itself a signaling molecule. It signals sirtuins, which signal mitochondrial function, which signal burning, which is good." (said at 0:28:32)

Preclinical evidence demonstrates that beta-hydroxybutyrate (BHB) acts as a signaling metabolite that upregulates and activates sirtuin enzymes (such as SIRT1 and SIRT3). Activation of these mitochondrial and nuclear sirtuins downstream promotes mitochondrial biogenesis, enhances mitochondrial membrane potential, and stimulates mitochondrial oxidative respiration and metabolic function.

0:29:40supportedhighTake Back Your Health - with Dr. Robert H. Lustig | The Empo

Wheat is a hexaploid organism rather than a diploid organism.

"Turns out wheat is a very complex organism. It's a hexaploid, not diploid, and there" (said at 0:29:40)

Common bread wheat (Triticum aestivum) is an allohexaploid organism (2n = 6x = 42 chromosomes) composed of three distinct subgenomes (A, B, and D), rather than a diploid organism (which possesses only two sets of chromosomes). It arose through natural hybridization between a tetraploid wheat progenitor (AABB) and the diploid wild grass Aegilops tauschii (DD).

0:30:02unverifiedvery lowTake Back Your Health - with Dr. Robert H. Lustig | The Empo

Wheat contains approximately 700 different antigens, of which gliadin and glutenin are two.

"are 700 different antigens. Two of them are gluten, so gliadin and glutenin, and those are the famous ones and those are the ones we have tests for. The other 698 we don't have tests for" (said at 0:30:02)

No published record matching the claim that wheat contains approximately 700 distinct antigens, with tests existing for only two (gliadin and glutenin) and 698 remaining untestable, was located; this does not prove the claim false. Proteomic and allergenomic studies show that wheat contains a diverse and complex array of both gluten (gliadins, glutenins) and non-gluten proteins (such as alpha-amylase/trypsin inhibitors, serpins, and agglutinins) capable of triggering immune responses. However, the specific quantification of 700 discrete antigens and the binary division regarding test availability are not substantiated in the peer-reviewed scientific literature.

0:35:54contradictedhighTake Back Your Health - with Dr. Robert H. Lustig | The Empo

Exercise does not reduce glycation and actually makes glycation worse.

"So it does not affect glycation; it actually makes glycation worse." (said at 0:35:54)

The claim that exercise does not reduce glycation and actually worsens it is directly contradicted by clinical trial and epidemiological evidence. Large meta-analyses of hundreds of randomized controlled trials show that exercise training consistently lowers glycated hemoglobin (HbA1c), a primary biomarker of protein glycation. Furthermore, a systematic review investigating the accumulation of advanced glycation end products (AGEs, measured via skin autofluorescence) found that higher physical activity and exercise levels are inversely associated with tissue glycation, with no studies finding that physical activity increases or worsens glycation accumulation.

0:35:59contradictedhighTake Back Your Health - with Dr. Robert H. Lustig | The Empo

Exercise does not reduce oxidative stress and actually makes oxidative stress worse.

"It does not affect oxidative stress; exercise actually makes oxidative stress worse." (said at 0:35:59)

The claim that exercise does not reduce oxidative stress and only worsens it is contradicted by systematic reviews and meta-analyses of randomized controlled trials. While a single, acute bout of strenuous exercise causes a transient increase in reactive oxygen species and oxidative stress biomarkers (such as protein carbonyls and F2-isoprostanes), regular exercise training induces adaptative increases in endogenous antioxidant enzymes (such as superoxide dismutase) and causes a net reduction in basal pro-oxidants and lipid peroxidation markers (such as malondialdehyde).

0:37:48supportedvery lowTake Back Your Health - with Dr. Robert H. Lustig | The Empo

Starving gut bacteria causes them to consume the intestinal epithelial mucin layer, reducing tight junction integrity and allowing lipopolysaccharides and bacteria to enter the bloodstream.

"And if you eat that mucin layer off your intestinal epithelial cells, now the bacteria are opposed right on your intestinal epithelial cells, and that has been shown to reduce the integrity of the tight junctions that basically keep your intestinal barrier. And so now you've got lipopolysaccharides and cytokines and bacteria themselves making their way through to your bloodstream" (said at 0:37:48)

The speaker accurately describes a mechanism demonstrated in gnotobiotic and murine models. Landmark research showed that when gut microbiota are deprived of dietary fiber, commensal bacteria switch to utilizing host-secreted mucin glycoproteins as an energy source. This degrades the protective colonic mucus layer, places bacteria in direct contact with the intestinal epithelium, disrupts mucosal barrier integrity, and facilitates bacterial translocation and inflammation. Because the complete causal chain is demonstrated primarily in animal models, the certainty of evidence for humans is very low.

0:39:11supportedmoderateTake Back Your Health - with Dr. Robert H. Lustig | The Empo

Colonic bacteria ferment soluble fiber into short-chain fatty acids, specifically propionate and butyrate, which exert anti-inflammatory and insulin-sensitizing effects.

"The colonic bacteria love soluble fiber, and they do you a favor because not only do they chew it up, but the waste product of their chewing up that fiber is short-chain fatty acids, propionate and butyrate, which turn out to be anti-inflammatory and anti-insulin for you." (said at 0:39:11)

Colonic bacterial fermentation of soluble dietary fiber produces short-chain fatty acids (SCFAs), principally acetate, propionate, and butyrate. A substantial body of preclinical research and human interventional trials demonstrates that these metabolites promote anti-inflammatory pathways, support intestinal barrier integrity, and improve insulin sensitivity and glycemic control.

0:42:57overstatedmoderateTake Back Your Health - with Dr. Robert H. Lustig | The Empo

Healthcare spending in the United States totals 3.6 trillion dollars annually, with 75% of that spending directed toward chronic metabolic diseases.

"medical care in this country costs 3.6 trillion dollars a year, and of that, 75% are all these chronic metabolic diseases that we've been talking about." (said at 0:42:57)

Official National Health Expenditure Accounts data from the Centers for Medicare & Medicaid Services reported total US healthcare spending at $3.6 trillion in 2018. While public health literature and the CDC frequently estimate that roughly 75% to 90% of US healthcare expenditures are driven by chronic diseases and conditions broadly, attributing this entire 75% share specifically to 'chronic metabolic diseases' is an overstatement. The broad chronic disease category encompasses a wide range of non-metabolic conditions, including musculoskeletal disorders, mental health disorders, cancers, dementia, and chronic respiratory diseases.

0:44:58needs contextmoderateTake Back Your Health - with Dr. Robert H. Lustig | The Empo

One out of every three new diabetes diagnoses in pediatric patients is type 2 diabetes.

"One out of every three new diabetes diagnoses is type 2 in kids" (said at 0:44:58)

Population surveillance from the SEARCH for Diabetes in Youth study shows that while type 1 diabetes remains the predominant form of pediatric diabetes, type 2 diabetes accounts for an increasing proportion of new diagnoses. Across the multi-center SEARCH registry (2002–2018), type 2 diabetes accounted for approximately 22.6% of new pediatric cases (5,293 of 23,462 total incident cases, or roughly 1 in 4.4). In recent years (2017–2018), type 2 diabetes incidence has risen significantly (annual incidence of 17.9 per 100,000 in youth aged 10–19 vs 22.2 per 100,000 for type 1 diabetes in youth aged 0–19), bringing the proportion of new diagnoses that are type 2 to roughly 1 in 3 to 1 in 4 across all youth, and even higher among adolescents aged 10–19 and racial/ethnic minority youth.

0:45:03overstatedmoderateTake Back Your Health - with Dr. Robert H. Lustig | The Empo

Twenty-five percent of children have fatty liver disease when evaluated by MRI.

"and 25% of kids, if you stick them in an MRI scanner, have fatty liver disease." (said at 0:45:03)

Large systematic reviews and meta-analyses show that the prevalence of non-alcoholic fatty liver disease (NAFLD / MASLD) in the general pediatric population is approximately 7% to 14%, not 25%. While hepatic steatosis prevalence reaches 38% to 41% among children with overweight or obesity, and adult global prevalence is approximately 25% to 30%, stating that 25% of children in general have fatty liver disease overstates general pediatric rates.

0:47:47supportedhighTake Back Your Health - with Dr. Robert H. Lustig | The Empo

Prohormone convertase 1 is the enzyme responsible for cleaving C-peptide from the proinsulin molecule to form mature insulin.

"prohormone convertase 1, which is the enzyme that cleaves the C-peptide out of the proinsulin molecule to make a mature, functional insulin." (said at 0:47:47)

Prohormone convertase 1 (also known as PC1 or PC1/3, encoded by PCSK1) is the primary endoprotease responsible for endoproteolytic cleavage of proinsulin to excise C-peptide and yield mature insulin. While classical models in rodents involved both PC1/3 and PC2 followed by carboxypeptidase E trimming, human beta-cell studies demonstrate that PC1/3 is the primary convertase required for proinsulin processing to mature insulin.

0:52:41needs contextmoderateTake Back Your Health - with Dr. Robert H. Lustig | The Empo

The reference range upper limit for alanine aminotransferase (ALT) in standard laboratory testing has shifted from 25 U/L in the 1970s up to 40 U/L today.

"I started in '76, and when I started, the upper limit for ALT was 25. Now today, if you pull out the lab slip and it just gives you the reference range, it tells you that the upper limit for ALT is 40." (said at 0:52:41)

Standard commercial laboratory reference intervals for alanine aminotransferase (ALT) have commonly reported upper limits of normal (ULN) around 40 U/L (and up to 45–55 U/L for men in many commercial assays). Epidemiological and clinical evaluations, such as the landmark study by Prati et al. (2002), demonstrated that traditional laboratory upper limits of 40 U/L for men and 30 U/L for women were established using reference populations that inadvertently included individuals with subclinical hepatic steatosis and occult viral hepatitis. When rigorously screened healthy cohorts are assessed, true physiological upper limits are lower (around 19–25 U/L in women and 30 U/L in men). While the speaker correctly notes that standard laboratory slips often report upper limits around 40 U/L despite true healthy thresholds being closer to 20–25 U/L, laboratory reference ranges vary widely by commercial assay and sex rather than reflecting a single uniform historical shift.

0:53:12contradictedmoderateTake Back Your Health - with Dr. Robert H. Lustig | The Empo

African Americans accumulate less hepatic fat on average due to a mutation in the APOC3 gene.

"In African Americans, it should be 20 for that matter because they actually don't even make as much fat in the liver. They have a mutation in their APOC3 gene, so they actually don't accumulate as much fat." (said at 0:53:12)

The claim that African Americans accumulate less hepatic fat due to a mutation in the APOC3 gene is contradicted by population-based genetics studies examining APOC3 variants, hepatic triglyceride content (HTGC), and ethnicity. In a large multiethnic cohort study (the Dallas Heart Study, n=1,228 African Americans), candidate APOC3 gene variants (rs2854117 and rs2854116) showed no significant difference in hepatic fat content between carriers and noncarriers, refuting the proposed role of APOC3 variants in driving lower hepatic fat accumulation in African Americans (PMID: 21274868). Similarly, in obese pediatric cohorts evaluated across racial groups, APOC3 gene variants were not associated with hepatic fat fraction, whereas variants in genes such as PNPLA3 and GCKR were associated with liver fat accumulation across ethnicities (PMID: 22105854).

0:54:43supportedhighTake Back Your Health - with Dr. Robert H. Lustig | The Empo

Hepatic fructose metabolism consumes ATP without a phosphate-scavenging pathway to return it, driving conversion of AMP into uric acid.

"when fructose enters the liver, ATP has to donate a phosphate. So ATP becomes ADP, and then it goes into AMP into uric acid. There's no scavenger mechanism to return that, so it goes to uric acid." (said at 0:54:43)

Published biochemical and clinical research confirms that hepatic fructose metabolism is initiated by ketohexokinase (fructokinase), which rapidly phosphorylates fructose to fructose-1-phosphate using ATP. Because ketohexokinase lacks negative feedback control and traps phosphate in fructose-1-phosphate, rapid ATP depletion occurs alongside intracellular phosphate depletion. This triggers adenylate kinase (converting ADP to AMP) and activates AMP deaminase (normally inhibited by inorganic phosphate), driving purine nucleotide degradation of AMP down the catabolic pathway into uric acid.

0:55:07unverifiedvery lowTake Back Your Health - with Dr. Robert H. Lustig | The Empo

Uric acid interferes with the mitochondrial enzyme carnitine palmitoyltransferase 1 (CPT-1).

"It has effects on the mitochondria because it interferes with the enzyme carnitine palmitoyltransferase 1, so it means that you're not getting stuff into your mitochondria to be able to get things burned." (said at 0:55:07)

No published record matching the claim that uric acid interferes with carnitine palmitoyltransferase 1 (CPT-1) was located; this does not prove the claim false.

0:55:17supportedmoderateTake Back Your Health - with Dr. Robert H. Lustig | The Empo

Uric acid is an endogenous inhibitor of endothelial nitric oxide synthase (eNOS), which contributes to elevated blood pressure.

"uric acid is the endogenous inhibitor of the enzyme in your blood vessels, endothelial nitric oxide synthase, or eNOS, which is your endogenous blood pressure lowerer. And so when your uric acid is high, your blood pressure goes up" (said at 0:55:17)

Preclinical in vitro and animal studies demonstrate that elevated uric acid directly impairs endothelial nitric oxide synthase (eNOS) phosphorylation and activity via the Akt pathway, reducing nitric oxide (NO) bioavailability and contributing to endothelial dysfunction and elevated blood pressure. In animal models, hyperuricemia raises arterial blood pressure, an effect reversible by lowering uric acid (e.g., with allopurinol) or enhancing the nitric oxide pathway (such as with L-arginine). Observational human studies also correlate higher serum uric acid with impaired endothelial function.

0:56:05unverifiedvery lowTake Back Your Health - with Dr. Robert H. Lustig | The Empo

Average salt intake prior to refrigeration was approximately 15 grams per day without widespread hypertension, compared to modern intake of 6.9 grams per day with a 40% incidence of hypertension.

"The average consumption of salt prior to refrigeration was about 15 grams of salt per day—15—and there was no hypertension. But today the average consumption of salt is 6.9 grams per day—half as much—and we have a 40% incidence of hypertension." (said at 0:56:05)

No published record matching the claim that average salt consumption prior to refrigeration was 15 grams per day without hypertension, compared to modern intake of 6.9 grams per day with a 40% incidence of hypertension, was located; this does not prove the claim false. Published evolutionary and historical reviews note that human populations evolved in low-salt environments and that dietary salt intake has markedly increased in recent decades alongside rising hypertension rates.

0:56:30supportedhighTake Back Your Health - with Dr. Robert H. Lustig | The Empo

Insulin promotes the reabsorption of sodium at the level of the kidney.

"Insulin helps resorb sodium, and so in the face of a high insulin, that 6.9 grams ends up being enormous." (said at 0:56:30)

The claim is supported. Insulin acts directly on multiple segments of the renal tubule (including the proximal tubule and collecting duct via channels such as ENaC) to facilitate renal sodium reabsorption, acutely decreasing urinary sodium excretion independently of the renin-angiotensin-aldosterone system.

1:00:26unverifiedvery lowTake Back Your Health - with Dr. Robert H. Lustig | The Empo

Neither Abraham Flexner nor Simon Flexner believed in nutrition, which led to nutrition not being taught in medical schools following the Flexner Report.

"And to be honest with you, that goes back 110 years to the Flexner Report, because neither Flexner, Abraham nor Simon, believed in nutrition." (said at 1:00:26)

No published record matching the claim that neither Abraham Flexner nor Simon Flexner believed in nutrition, or that their personal disbelief in nutrition led to its exclusion from medical school curricula following the Flexner Report, was located; this does not prove the claim false.

1:01:10overstatedhighTake Back Your Health - with Dr. Robert H. Lustig | The Empo

Homocysteine drives cardiovascular smooth muscle proliferation and leads to heart attacks.

"So homocysteine is a driver of cardiovascular smooth muscle proliferation. It is one of the things that leads to heart attacks." (said at 1:01:10)

Preclinical and mechanistic studies confirm that elevated homocysteine promotes vascular smooth muscle cell (VSMC) proliferation, migration, and phenotypic switching in vitro and in animal models. Furthermore, observational epidemiology shows an association between hyperhomocysteinemia and cardiovascular risk. However, the claim that homocysteine directly leads to heart attacks is overstated. High-certainty evidence from large-scale randomized controlled trials and a Cochrane systematic review involving over 46,000 participants shows that lowering plasma homocysteine levels with B-vitamin supplementation (folic acid, B6, and B12) does not reduce the incidence of myocardial infarction (RR 1.02, 95% CI 0.95 to 1.10) or all-cause mortality, indicating that homocysteine is a marker or correlated risk factor rather than an independent causal driver of heart attacks in humans.

1:01:26contradictedhighTake Back Your Health - with Dr. Robert H. Lustig | The Empo

Homocysteine is normally metabolized through the urea cycle to succinate by the enzyme methylenetetrahydrofolate reductase (MTHFR).

"And the thing is that homocysteine is normally metabolized down the urea cycle to succinate by the enzyme MTHFR, methylenetetrahydrofolate reductase." (said at 1:01:26)

The speaker fundamentally misstates the biochemistry of homocysteine metabolism. Homocysteine is not metabolized through the urea cycle to succinate by methylenetetrahydrofolate reductase (MTHFR). In human biochemistry, homocysteine has two major pathways: remethylation back to methionine and transsulfuration to cysteine. MTHFR catalyzes the conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, which provides the methyl group used by methionine synthase to remethylate homocysteine into methionine. The urea cycle is a distinct pathway responsible for ammonia detoxification, and succinate is an intermediate of the citric acid (TCA) cycle.

1:03:12overstatedmoderateTake Back Your Health - with Dr. Robert H. Lustig | The Empo

Only 28% of US medical schools have a nutrition curriculum.

"Well, only 28% of medical schools even have a nutrition curriculum, and there's no CMEs for nutrition, except some rare things like integrative medicine at University of Arizona" (said at 1:03:12)

The cited figure appears to conflate national survey findings on medical school nutrition education. In a national survey of accredited U.S. medical schools by Adams et al. (2010), 94.5% (103/109) of responding schools required some form of nutrition education, typically integrated into other courses. However, only 25% (26/105) required a dedicated, standalone nutrition course, and only 27% (28/105) met the National Academy of Sciences recommendation of at least 25 total hours of nutrition instruction. While nutrition training in medical schools remains limited, claiming that only 28% have any nutrition curriculum misrepresents the data.

1:03:32needs contexthighTake Back Your Health - with Dr. Robert H. Lustig | The Empo

California requires physicians to complete 12 hours of continuing medical education (CME) in palliative care to maintain their medical license.

"In California, I had to take 12 hours of palliative care. As an endocrinologist, I had to take 12 hours of palliative care... they made me do that to keep my license, but no one says a damn thing about nutrition." (said at 1:03:32)

California law (under Business and Professions Code Section 2190.5, originally enacted via Assembly Bill 487 in 2001) mandates a one-time 12-hour continuing medical education (CME) requirement in pain management and the care of terminally ill and dying patients for licensed physicians and surgeons in California. While the speaker accurately states that physicians (including endocrinologists) practicing in California are required to complete 12 hours of CME covering palliative and end-of-life care / pain management to maintain licensure, it is a one-time requirement upon initial licensure or renewal rather than a recurring requirement for every license renewal cycle, and certain specialties (such as pathology and radiology) are exempt. Standard CME surveys across US states reflect widespread state-mandated topic-specific CME requirements for physician licensure (such as pain management and opioid prescribing), though these mandates vary by state and specialty relevancy. No published study was located that directly addresses or verifies the speaker's comparative statement regarding nutrition education requirements relative to palliative care CME requirements in California.

1:06:15overstatedhighTake Back Your Health - with Dr. Robert H. Lustig | The Empo

Following the Master Settlement Agreement, cigarette consumption in America decreased by more than half.

"and now we have the Master Settlement Agreement and we have something at least to change cigarette consumption in America, and it did go down, you know, it got cut in more than half after that." (said at 1:06:15)

While the 1998 Master Settlement Agreement (MSA) led to price increases and reductions in smoking rates and overall cigarette consumption, claiming that consumption was 'cut in more than half after that' significantly overstates the impact. Econometric evaluations of nationwide population data following the settlement found much more modest declines: by 2002, the MSA was estimated to have reduced overall smoking rates by 5% among adults aged 21 to 64, and by 13% among young adults (ages 18–20) and seniors (65+).

1:07:37unverifiedvery lowTake Back Your Health - with Dr. Robert H. Lustig | The Empo

Insulin drives the production of ACE2 on the cell surface.

"Insulin: turns out insulin drives ACE2—ACE2, angiotensin-converting enzyme 2. Now, that is normally a water channel in cells, especially lung, but it drives the production of ACE2." (said at 1:07:37)

No published record matching the claim that insulin drives the production of ACE2 on the cell surface was located; this does not prove the claim false. In addition, angiotensin-converting enzyme 2 (ACE2) functions physiologically as a membrane-bound carboxypeptidase within the renin-angiotensin system—converting angiotensin II into angiotensin-(1-7)—rather than serving as a cellular water channel (a role performed by aquaporins).

1:07:40contradictedhighTake Back Your Health - with Dr. Robert H. Lustig | The Empo

ACE2 is normally a water channel in cells, especially in the lungs.

"ACE2, angiotensin-converting enzyme 2. Now, that is normally a water channel in cells, especially lung, but it drives the production of ACE2." (said at 1:07:40)

ACE2 (angiotensin-converting enzyme 2) is not a water channel; it is a membrane-bound zinc carboxypeptidase within the renin-angiotensin system that cleaves angiotensin II into angiotensin-(1-7) and serves as the cellular entry receptor for SARS-CoV and SARS-CoV-2. The cellular proteins that function as water channels are aquaporins (e.g., AQP1 through AQP5), which the speaker may have confused with ACE2 due to the similar abbreviation of Aquaporin-2 (AQP2).

1:07:55supportedhighTake Back Your Health - with Dr. Robert H. Lustig | The Empo

SARS-CoV-2 uses ACE2 as its entry point to infect cells.

"Because that COVID virus is so freaking goddamn smart, it uses ACE2 as its entry point. And so the more molecules of ACE2 you have on the surface of your cell, the more chance that that virus is going to infect you." (said at 1:07:55)

Extensive in vitro and molecular studies established early in the COVID-19 pandemic that SARS-CoV-2 utilizes angiotensin-converting enzyme 2 (ACE2) as its primary functional host cell entry receptor. Binding of the viral spike glycoprotein to cell-surface ACE2 enables viral attachment and subsequent host cell entry (often facilitated by host proteases such as TMPRSS2).

1:08:20overstatedvery lowTake Back Your Health - with Dr. Robert H. Lustig | The Empo

Short-chain fatty acids suppress the immune system and inhibit the cytokine storm caused by COVID-19, reducing mortality.

"Turns out those short-chain fatty acids are immunosuppressive and keep the cytokine storm that the virus generates at a low ebb, and so that will keep you from succumbing to massive cytokine storm from being so sick with COVID. So that will reduce mortality rates." (said at 1:08:20)

The claim is overstated. Published mechanistic and observational studies show that short-chain fatty acids (SCFAs, such as butyrate) possess immunomodulatory and anti-inflammatory properties that can dampen cytokine production and lung inflammation via the gut-lung axis. Furthermore, observational data correlate higher levels of SCFA-producing gut bacteria with milder COVID-19 severity and lower population-level mortality. However, stating definitively that SCFAs suppress the cytokine storm in COVID-19 to reduce clinical mortality overstates the evidence, as this reflects hypotheses, preclinical mechanistic models, and observational correlations rather than proven clinical trial outcomes in humans.

1:08:40contradictedmoderateTake Back Your Health - with Dr. Robert H. Lustig | The Empo

High blood glucose crystallizes around ACE2 molecules to keep them open, increasing susceptibility to COVID-19 infection.

"High blood glucose basically crystallizes around the edges of those ACE2 molecules and keeps them open so that the virus has an even easier chance of infecting you." (said at 1:08:40)

The claim mischaracterizes the biochemistry of hyperglycemia and SARS-CoV-2 receptor interaction. Glucose does not physically "crystallize" on cell-surface receptors in aqueous biological fluids. In patients with elevated blood glucose, the actual molecular mechanism involves non-enzymatic glycation (the covalent attachment of glucose molecules to lysine residues) and increased cellular expression of ACE2. Furthermore, in silico structural modeling indicates that glycation of ACE2 residues reduces polar and van der Waals interactions with the viral Spike protein rather than mechanically holding the receptor open.

1:09:00supportedmoderatetheir own paperTake Back Your Health - with Dr. Robert H. Lustig | The Empo

Studies at UCSF showed that eating real food reduces insulin, fatty liver, uric acid, and ALT in nine days.

"We have shown in our studies at UCSF that you can get your insulin down, and you can get your fatty liver down, and you can get your uric acid and your ALT down in nine days—nine days—by eating real food." (said at 1:09:00)

Studies conducted by Dr. Robert Lustig and colleagues at UCSF (such as the 2016 Obesity trial and 2017 Gastroenterology publication) tested a 9-day dietary intervention in children with obesity and metabolic syndrome. In these studies, dietary sugar/fructose was restricted and substituted isocalorically with starch. The trials demonstrated rapid, statistically significant reductions in hyperinsulinemia and insulin kinetics, liver fat (hepatic steatosis measured via magnetic resonance spectroscopy decreased from a median of 7.2% to 3.8%), visceral fat, and circulating metabolic biomarkers over the 9-day period. Describing this intervention as 'eating real food' refers to the study's design of removing processed/added sugars from the children's diets.

1:09:32needs contextmoderateTake Back Your Health - with Dr. Robert H. Lustig | The Empo

The average American consumes 7.5 servings of ultra-processed foods per day.

"And yet the average American is eating 7.5 servings of ultra-processed foods every day right now" (said at 1:09:32)

Dietary studies in large US prospective cohorts (such as the Nurses' Health Study and the Health Professionals Follow-up Study) and national surveys measure ultra-processed food (UPF) consumption ranging between approximately 5.7 and 7.5 servings per day (accounting for nearly 60% of daily caloric intake in the general US population). In these cohorts, 7.4 to 7.5 servings per day typically represents the upper intake categories (e.g., the highest quartile or top of the interquartile range), while the median intake is around 5.7 to 6.5 servings per day.

Fact-checked episodes

Publications